Michael Michael

The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases

Michael P Flood, Anshini Jain, Catherine Mitchell, Chelsee Hewitt, Robert Ramsay, Michael Michael, Alexander G Heriot, Jeanne Tie

Journal article  |  2022  |  EJSO

BACKGROUND: Stratification of patients with colorectal peritoneal metastases (CRPM) using RAS/BRAF mutational status may refine pa..

Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei

Michael P Flood, Joseph C Kong, Toan Pham, Peadar S Waters, Mikael Soucisse, Robert Ramsay, Hui-Li Wong, Catherine Mitchell, Michael Michael, Jacob J McCormick, Satish K Warrier, Tim Akhurst, Alexander G Heriot

Journal article  |  2022  |  EJSO

BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare clinical entity, commonly derived from a mucin-producing tumour of the appendix..

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping

Cassandra White, Rodney J Scott, Christine Paul, Andrew Ziolkowski, David Mossman, Stephen B Fox, Michael Michael, Stephen Ackland

Journal article  |  2022  |  CLINICAL PHARMACOLOGY & THERAPEUTICS

Fluoropyrimidines (FP; 5-fluorouracil, capecitabine, and tegafur) are a commonly prescribed class of antimetabolite chemotherapies..

ATRT-17. A phase II study of continuous low dose panobinostat in paediatric patients with malignant rhabdoid tumours and atypical teratoid rhabdoid tumours.

Paul Wood, Jayesh Desai, Kelly Waldeck, Jason Cain, Nicholas Gottardo, Robyn Strong, Kathryn Kinross, Michelle Carr, Janelle Jones, Lily Wong, David Ziegler, Jordan Hansford, Michael Michael, David Ashley

Conference Proceedings  |  2022  |  Neuro-Oncology

Abstract BACKGROUND: Panobinostat treatment has been shown to terminally differentiate malignant rhabdoid tumours (..

Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).

Li-Yuan Bai, Teresa Macarulla, Peter Grell, Cheng Ean Chee, Anuradha Krishnamurthy, Mark Ka Wong, Michael Michael, Michele Milella, Gerald Prager, Christoph Springfeld, Joelle Collignon, Jens Siveke, Armando Santoro, Chia-Chi Lin, Katriina Johanna Peltola, Geraldine Bostel, Dragana Jankovic, Maria-Athina Altzerinakou, Claire Fabre, Shivan Sivakumar

Conference Proceedings  |  2022  |  Journal of Clinical Oncology

TPS4183 Background: Overall survival remains low for pts with mPDAC despite approved therapies, highlighting the need for further..

Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)—Final results.

Nick Pavlakis, David Turner Ransom, David Wyld, Katrin Marie Sjoquist, Kate Wilson, Val Gebski, James Murray, Andrew Ddembe Kiberu, Matthew E Burge, William Macdonald, Paul Roach, David A Pattison, Patrick Butler, Timothy Jay Price, Michael Michael, Benjamin James Lawrence, Dale L Bailey, Simone Leyden, John Raymond Zalcberg, Harvey Turner

Conference Proceedings  |  2022  |  Journal of Clinical Oncology

4122 Background: CAPTEM is an accepted regimen for patients (pts) with advanced pNETs. Single agent PRRT is now a standard of car..

Risk assessment model potency to detect patients most likely to benefit from thromboprophylaxis: An application of the TARGET-TP score.

Kate Burbury, Marliese Alexander, Samuel J Harris, Craig Underhill, Javier Torres, Sharad Sharma, Nora Lee, Hui-Li Wong, Richard Wilhelm Eek, Michael Michael, Jeanne Tie, Jennifer Rogers, Alexander Graham Heriot, David Ball, Michael Patrick MacManus, Rory Wolfe, Benjamin J Solomon

Conference Proceedings  |  2022  |  Journal of Clinical Oncology

12116 Background: Interventional trials applying risk models for targeted-thromboprophylaxis (TP) for ambulatory cancer patients ..

Exploring health professional knowledge and management of nutritional complications in neuroendocrine cancer patients: Results of an international multidisciplinary survey

Erin Laing, Nicole Kiss, Meinir Krishnasamy, Karla Gough, Michael Michael

Journal article  |  2022  |  CLINICAL NUTRITION ESPEN

BACKGROUND AND AIMS: Patients with neuroendocrine tumours (NET) are at nutritional risk due to symptoms and treatment side-effects..

Real-world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma

Alexander Grogan, Benjamin Loveday, Michael Michael, Hui-Li Wong, Peter Gibbs, Benjamin Thomson, Belinda Lee, Hyun Soo Ko

Journal article  |  2022  |  ANZ JOURNAL OF SURGERY

BACKGROUND: Computed tomography (CT) is the first-line staging imaging modality for pancreatic ductal adenocarcinoma (PDAC) which ..

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases in an elderly population: outcomes from a single centre

Michael P Flood, Vignesh Narasimhan, Peadar S Waters, Joseph C Kong, Robert Ramsay, Michael Michael, Jeanne Tie, Jacob J McCormick, Satish K Warrier, Alexander G Heriot

Journal article  |  2022  |  ANZ JOURNAL OF SURGERY

BACKGROUND: The prevalence of elderly patients with resectable colorectal peritoneal metastases (CRPM) is increasing. This study a..